COVID-19 Vaccine Impact on Cell Lysis & Disruption Market Is Expected At A CAGR Of 8.31% 2025

The global cell lysis & disruption market size is expected to reach USD 5.65 billion by 2025 registering a CAGR of 8.31%, according to a new report by Grand View Research, Inc. Demand for cell lysis & disruption is driven by the immense growth of the biotechnology sector globally. This is majorly due to the high adoption of biotech processes in the pharmaceutical, agricultural, and bio-services industries.

Technological developments in procedures involved to release cellular organelles have paved the way for higher adoption of cell disruption methods. As retrieval and purification of biopharmaceuticals involve cell disruption, a rise in demand for biopharma would lead to the subsequent growth of the market. In addition, advancements in the field of proteomics, metabolomics, and personalized medicine are expected to fuel progressive changes in this sector. However, the high cost of equipment coupled with the dearth of skilled professionals is expected to restrain revenue generation to a certain extent.

The restraint can be addressed as the government organizations are releasing substantial funds to fuel development in the biotechnology sector. Merck KGaA; Thermo Fisher Scientific, Inc.; Qiagen NV; F. Hoffmann-La Roche Ltd; Becton Dickinson & Company (BD); Bio-Rad Laboratories, Inc.; Danaher Corporation; Claremont BioSolutions, LLC; and Miltenyi Biotec GmbH are the prominent companies in this market. These companies have undertaken strategies, such as new product development and strategic alliances, to maintain their market share.

To request a sample copy or view summary of this report, click the link below:
www.grandviewresearch.com/industry-analysis/cell-lysis-dissociation-market

Further key findings from the study suggest:

  • A rise in development of biologics has subsequently led to a high demand for better bioprocess solutions
  • The advantages offered by reagent-based methods for isolation of biological products is attributive to the largest share of the segment in 2018
  • The advantages include an unaltered biological activity of the sample of interest and ideal compatibility with the laboratory reagents
  • Enzymatic lysis, owing to higher biological specificity, is anticipated to be the fastest-growing segment over the forecast period
  • Sonication instruments are expected to witness the maximum CAGR from 2019 to 2025 due to higher adoption rate of these products due to their reliability
  • Mammalian cell culture systems have grabbed substantial attention among the biopharmaceutical manufacturers, thus leading to higher demand for cell lysis protocols for the same
  • Academic research accounted for the largest share in 2018 as a result of higher usage of cell separation associated protocols in research facilities
  • Substantial research in the development of the nucleic acid-derived products is expected to drive progress in this application in the coming years
  • APAC is projected to be the fastest-growing regional cell lysis & disruption market due to lucrative opportunities offered by emerging nations, which has attracted investments from global firms
(Visited 1 times, 1 visits today)

Comments

comments

You may also like...